Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
AbbVie today announced that the United States Food and Drug Administration (FDA) has approved expanding […]
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
AbbVie has announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg [induction dose] and 15 […]
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
AbbVie and Capsida Biotherapeutics today announced an expanded strategic collaboration to develop genetic medicines for […]
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators
AbbVie and Anima Biotech (Anima) today announced a collaboration to discover and develop mRNA biology modulators […]
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
AbbVie and Immunome, a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform […]
RINVOQ ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved […]
AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. (‘Richter’) today announced a new co-development and license […]
AbbVie and REGENXBIO Announce Eye Care Collaboration
AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and […]
AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration […]
New Data Shows AbbVie's VENCLYXTO/VENCLEXTA Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more